Lee Han-Soo writing for Korean Biomedical Review reports that JW Pharmaceutical has received approval from the Korean Ministry of Food and Drug Safety to commence with a Phase 2b clinical trial for its URC102 gout treatment. Gout is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot and swollen joint. It can be extremely painful and can result in tophi, kidney stones or urate nephropathy. Potentially caused by a combination of diet and genetic factors, Gout is due to persistently elevated levels of uric acid in the blood. Gout impacts about 2% of the population in the western world.
JW Pharma believes existing gout drugs that promote uric acid discharge are not actively prescribed due to safety concerns. Because it is a disease with a high demand for an effective treatment, the company plans to diversify their opportunities to advance into the global market with their Phase 2b clinical trials.
URC102 was originated by both JW Pharmaceutical and Chugai Pharmaceutical (Roche).
It is reported that Gout cases has grown by 40 percent over the last several years according to Health Insurance Review and Assessment Service. The global market for Gout is estimated to reach $3 trillion won ($2.6 billion) in 2019.